Metformin in cancer: translational challenges

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Metformin is a widely used anti-diabetic medication for type 2 diabetes and insulin resistance syndromes.
• Epidemiological studies suggest a correlation between metformin use and reduced cancer incidence and mortality.
• Preclinical and clinical research indicates metformin possesses anti-cancer properties.

Purpose of the Study:

• To review the mechanisms of action of metformin as an anti-cancer agent.
• To summarize evidence supporting metformin's role in cancer treatment.
• To discuss challenges in translating preclinical findings to clinical benefits.

Main Methods:

• Review of epidemiological studies.
• Analysis of preclinical research findings.
• Evaluation of clinical trial data.

Main Results:

• Metformin improves insulin resistance by affecting hepatic gluconeogenesis and glucose uptake.
• Metformin use is linked to lower cancer incidence and mortality.
• Evidence suggests metformin may target cancers associated with hyperinsulinemia and directly inhibit tumor growth.

Conclusions:

• Metformin demonstrates potential as an anti-cancer therapeutic.
• Further research is needed to overcome challenges in clinical application.
• Metformin's dual role in diabetes and cancer warrants continued investigation.